Consorcio Hospitalario Provincial de Castelló
- Address
- Avenida Doctor Clará, 19, 12002 Castellon, Spain
Consorcio Hospitalario Provincial de Castelló - Oncology Research Center
Consorcio Hospitalario Provincial de Castelló is a prominent research institution dedicated to advancing cancer treatment through innovative clinical trials. The center specializes in evaluating novel therapeutic approaches and precision medicine strategies for various malignancies, with a particular emphasis on immunotherapy and targeted therapies.
- Advanced Non-Small Cell Lung Cancer (NSCLC) with focus on combination immunotherapy and cancer vaccine development
- HER2-positive early-stage breast cancer utilizing chemotherapy-free, pathological complete response-guided treatment strategies
- PD-L1 checkpoint inhibitor therapy and biomarker-driven patient selection
The facility demonstrates expertise in conducting complex oncology trials that evaluate both efficacy and safety outcomes, including objective response rates, recurrence-free intervals, and quality-of-life assessments. Their research portfolio reflects a commitment to developing personalized treatment approaches that may minimize toxicity while optimizing therapeutic benefit for cancer patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Regeneron Pharmaceuticals Inc.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Consorcio Hospitalario Provincial de Castelló
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of a Chemotherapy-Free Pathological Complete Response-Guided Strategy Using Subcutaneous Trastuzumab, Pertuzumab, and Trastuzumab Emtansine in HER2-Positive Early Breast Cancer | Medica Scientia Innovation Research S.L. | Phase II | Not Recruiting | Jun 2021 | — |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cemiplimab | 1 | Unknown | 2024-04-18 | 2024-04-18 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.